Mid-Atlantic Life Sciences & Biotech Summit in Maryland

After an explosive pandemic-era expansion, the Mid-Atlantic life sciences market is undergoing a reset. According to Cushman & Wakefield, availability in Suburban Maryland alone has climbed to a record 20.2%, with 14% vacancy and more space expected to hit the market as venture funding slows, federal budget cuts reduce new tenant formation, and several firms face bankruptcy or capital shortfalls.

These conditions are pushing landlords to rethink their strategies. Owners of large life science blocks are actively pursuing medical office conversions, alternative uses, and flexible buildouts to widen the tenant pool and stabilize occupancy. The market’s transition is reshaping underwriting assumptions and forcing a sharper focus on adaptable, future-proof space.

For tenants, this is a highly favorable moment: rental rates remain steady in the low-to-mid $40s psf, while landlords are offering shorter terms, richer concessions, and more negotiable deal structures. Early-stage companies, in particular, are gravitating toward spec suites and second-generation lab space that minimize upfront capital.

For market participants, success will hinge on flexibility, creative repositioning, and understanding a tenant-driven landscape in flux. Join our panel of experts, from venture capitalists to developers, occupiers and associations, to understand how to position yourself best for success in today’s evolving and rapidly-changing market.

What You’ll Learn: 

• How are changes in tenant demand for life sciences spaces influencing the design and development of lab and office environments, particularly in the Mid-Atlantic, and what trends are emerging to accommodate evolving needs in functionality, flexibility, and sustainability?
• With the current supply and demand imbalance in major lab markets, how are developers and investors adjusting their strategies for life sciences companies over the next 12 to 18 months?
• As the region’s life sciences market sees positive absorption, especially with recent leases like BeMoreLabs, how can developers and investors capitalize on the demand for lab space in the area amidst rising construction costs?
• Given the shifts in policies under the Trump administration, how do you expect changes in drug pricing strategies, supply chain regulations and acquisition activity to impact life sciences real estate demand?
• How can Maryland, DC and Virginia invest in innovation programs to help enhance their role as a leader in life sciences innovation and support small businesses entering the market?

Who You’ll Meet: Developers, owners, investors, construction, designers, architects, financial professionals and more!